Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level ≤ 10 ng/ml: Radiation therapy or surgery?
- 1 July 1997
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 38 (4), 723-729
- https://doi.org/10.1016/s0360-3016(97)00123-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancerUrology, 1996
- Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic CarcinomaJournal of Urology, 1995
- A Multivariate Analysis of Clinical and Pathological Factors that Predict for Prostate Specific Antigen Failure after Radical Prostatectomy for Prostate CancerJournal of Urology, 1995
- Pre-treatment psa as a predictor of long-term outcome in patients definitively irradiated for prostatic carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1994
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- Correlation of pathologic findings with progression after radical retropubic prostatectomyCancer, 1993
- Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: FollowupJournal of Urology, 1993
- Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical ProstatectomyJournal of Urology, 1993
- Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the ProstateJournal of Urology, 1991
- Radical Surgery Versus Radiotherapy for Adenocarcinoma of the ProstateJournal of Urology, 1982